

## Monday, October 22, 2007

**10:00 AM-8:00 PM**      **Registration**  
First Floor Lobby

**1:30 PM-3:30 PM**      **Educational Session 1:  
Predictive Biomarkers and  
Functional Imaging as Aids to  
Drug Development**  
Room 2014

**Chairperson: Julius Leyton**, Imperial College,  
London, England

PET Tracers as Biomarkers in Oncology  
Drug Development\*

**Julius Leyton**, Imperial College, London, England

Pharmacogenomic Applications in Oncology  
Drug Development

**Nicholas C. Dracopoli**, Bristol-Myers Squibb  
Company, Princeton, NJ, USA

Functional Imaging as Aids to Drug Development

**Patricia M. Price**, Christie Hospital NHS Trust,  
Manchester, England

**3:30 PM-5:30 PM**      **Educational Session 2:  
Micro and Interfering  
RNAs in Disease Causation,  
Target Validation, and  
Cancer Treatment**  
Room 2014

**Chairperson: Frank Slack**, Yale University,  
New Haven, CT, USA

MicroRNAs in Cancer\*

**Frank Slack**, Yale University, New Haven, CT, USA

MicroRNAs as Biomarkers in Cancer Risk and Response\*

**Joanne B. Weidhaas**, Yale University School of  
Medicine, New Haven, CT, USA

Toward a Non-Coding RNA Revolution in the  
Cancer Society

**George Adrian Calin**, University of Texas M. D.  
Anderson Cancer Center, Houston, TX, USA

miRNAs as Oncogenes, Tumor Suppressors, and  
Therapeutic Intervention Points

**David Brown**, Asuragen, Inc., Austin, TX, USA

**6:00 PM-7:30 PM**      **Opening Reception**  
San Francisco Marriott  
Yerba Buena Ballroom, Salon 7/8

## Tuesday, October 23, 2007

**7:00 AM-8:00 AM**      **Continental Breakfast**  
Third Floor Lobby

**8:00 AM-8:05 AM**      **Opening Remarks**  
Third Floor Ballroom

**Sara A. Courtneidge**, **James H. Doroshov**,  
**and Alexander M. M. Eggermont**, Scientific  
Committee Chairpersons

**8:05 AM-10:05 AM**      **Keynote Addresses**  
Third Floor Ballroom

Molecular Profiling and Breast Cancer: Towards Better  
Risk Estimation, Prognostication, and Prediction\*

**Anne-Lise Børresen-Dale**, Norwegian Radium  
Hospital, Oslo, Norway

Discovery of Disease Alleles and Drug Targets in  
Myeloid Leukemias

**Dwight Gary Gilliland**, Harvard Medical School,  
Boston, MA, USA

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**10:05 AM-10:30 PM**    **Coffee Break**  
Third Floor Lobby

**10:30 AM-12:30 PM**    **Plenary Session 1:  
Cancer Stem Cells**  
Third Floor Ballroom

**Chairperson:** Peter B. Dirks, Hospital for Sick Children,  
Toronto, ON, Canada

Brain Tumor Stem Cells: Chemical Determinants of  
Self Renewal

**Peter B. Dirks**, Hospital for Sick Children, Toronto,  
ON, Canada

Examining the Role of Stem Cell Biology  
in Lung Cancer\*

**Carla Kim**, Children's Hospital, Boston, MA, USA

Characterization and Targeting of Human Leukemia  
Stem Cells\*

**Craig T. Jordan**, James P. Wilmot Cancer Center,  
University of Rochester, Rochester, NY, USA

Cancer Stem Cells in Head and Neck Squamous  
Cell Carcinoma\*

**Laurie Ailles**, Stanford University School of Medicine,  
Palo Alto, CA, USA

**12:30 PM-2:30 PM**    **Poster Session A/Exhibits**  
First Floor Exhibit Hall

**2:30 PM-4:30 PM**    **Plenary Session 2: Targeting  
DNA Repair Pathways**  
Third Floor Ballroom

**Chairperson:** Alan Ashworth, Institute of Cancer  
Research, London, England

DNA Damage-Activated Kinases as Targets for  
Cancer Therapy\*

**Roger J. Griffin**, Newcastle University, Newcastle  
upon Tyne, England

Targeting Fanconi Anemia/BRCA Pathway Defects in  
Cancer Therapeutics\*

**Alan D. D'Andrea**, Dana-Farber Cancer Institute,  
Harvard Medical School, Boston, MA, USA

Right Silencing and Stratified Therapy in Glioblastoma\*  
**Monika E. Hegi**, University Hospital, Lausanne,  
Switzerland

ERCC1 as Relevant Targets in the DNA Repair Pathway\*  
**Jean-Charles Soria**, Institut Gustave-Roussy,  
Villejuif, France

**4:30 PM-5:30 PM**    **Proffered Paper Session 1**  
Third Floor Ballroom

PR-1 Inhibition of IGF-1R by OSI-906 Potentiates  
Efficacy of Various Molecular Targeted Agents by  
Blocking Feedback Loops Converging at the Level  
of IRS-1\*

**Elizabeth Buck**, OSI Pharmaceuticals, Inc.,  
Farmingdale, NY, USA

PR-2 Design, Synthesis, and Evaluation of Bivalent  
Conformationally Constrained Smac Mimetics  
that Concurrently Target both BIR2 and BIR3 Domain  
of XIAP\*

**Haiying Sun**, University of Michigan, Ann Arbor, MI, USA

PR-3 RNAi Screening Identifies TAK1 as a Potential  
Target for the Enhanced Efficacy of Traditional  
Cytotoxic Agents in Breast Cancer Cells\*


**Scott E. Martin**, National Cancer Institute,  
Bethesda, MD, USA

PR-4 Breast Cancer Cells Resistant to Anti-hormone  
Treatments Retain Sensitivity to Aminoflavone  
(NSC 686288)\*

**Phillip Shelton**, University of Maryland, School of  
Medicine, Baltimore, MD, USA

**5:30 PM-7:30 PM**    **Poster Session A/Exhibits  
(continued)**  
First Floor Exhibit Hall

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.



## Wednesday, October 24, 2007

**7:00 AM-8:00 AM**      **Continental Breakfast**  
Third Floor Lobby

**8:00 AM-10:00 AM**    **Plenary Session 3:  
Epigenetic Targets**  
Third Floor Ballroom

**Chairperson: Kristian Helin**, University of Copenhagen, Copenhagen, Denmark

Epigenetic Control and the Development of Cancer\*  
**Kristian Helin**, University of Copenhagen, Copenhagen, Denmark

Title to Be Announced  
**Stephen B. Baylin**, Johns Hopkins University School of Medicine, Baltimore, MD, USA

The Cancer Epigenome\*  
**Peter A. Jones**, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Chromatin Alterations in Leukemias\*  
**Pier Giuseppe Pelicci**, European Institute of Oncology, Milan, Italy

**10:00 AM-10:30 AM**    **Coffee Break**  
Third Floor Lobby

**10:30 AM-12:30 PM**   **Plenary Session 4:  
Genome-wide Approaches  
to Diagnosis, Stratification,  
and Target Identification**  
Third Floor Ballroom

**Chairperson: Louis M. Staudt**, National Cancer Institute, Bethesda, MD, USA

Predicting Effectiveness and Understanding Resistance to Targeted Inhibitors: Lessons from EGFR in Lung Cancer  
**Daniel A. Haber**, Massachusetts General Hospital, Charlestown, MA, USA

Cancer Genetic Markers of Susceptibility: Genome-wide Association Studies in Breast and Prostate Cancer  
**Stephen Chanock**, National Cancer Institute, Bethesda, MD, USA

Mechanisms of Resistance to NOTCH1 Inhibitors in T-ALL  
**Adolfo Ferrando**, Columbia University Medical Center, New York, NY, USA

From Genomic Diversity to Tumor Dependency in Human Cancer\*  
**Levi A. Garraway**, Dana-Farber Cancer Institute, Boston, MA, USA

**12:30 PM-2:30 PM**    **Poster Session B/Exhibits**  
First Floor Exhibit Hall

**2:30 PM-4:30 PM**    **Concurrent Session 1:  
High Throughput Screens  
for Target Identification**  
Room 2001

**Chairperson: René Bernards**, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Biomarkers of Resistance to Cancer Therapy Discovered through Functional Genetic Screens\*  
**René Bernards**, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Functional Genomics of Chemosensitivity Exposes Deviant Cancer Cell Regulatory Systems  
**Michael A. White**, University of Texas Southwestern Medical Center, Dallas, TX, USA

Achilles Heel RNA Interference Screens for Molecular Targets in Cancer\*  
**Louis M. Staudt**, National Cancer Institute, Bethesda, MD, USA

Using Cellular Pharmacogenomics to Identify and Prioritize Genetic Determinants of Drug Response  
**Jeffrey M. Trent**, TGen, Phoenix, AZ, USA

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**2:30 PM-4:30 PM**      **Concurrent Session 2:  
Small Molecule Approaches to  
the Regulation of Apoptosis**  
Room 2007

**Chairperson: Louis J. Lombardo**, Bristol-Myers Squibb Company, Princeton, NJ, USA

Design of Small-molecule SMAC Mimetics as Apoptosis Inducers in Tumor Cells: Molecular Insights into Apoptosis Regulation

**Shaomeng Wang**, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

Drugging "Undruggable" Targets\*

**Gregory L. Verdine**, Harvard University, Cambridge, MA, USA

Structure-based Design of IAP Antagonists\*

**Wayne J. Fairbrother**, Genentech, Inc., South San Francisco, CA, USA

Apoptosis Based Therapies from a Medicinal Chemistry Perspective\*

**Maurizio Pellecchia**, Burnham Institute for Medical Research, La Jolla, CA, USA

**2:30 PM-4:30 PM**      **Concurrent Session 3:  
Tumor Microenvironment  
and Metastasis**  
Room 2014

**Chairperson: Valerie M. Weaver**, University of California, San Francisco, CA, USA

Spatial-Mechanical Cues from the Microenvironment Modulate Malignant Transformation and Treatment Efficacy

**Valerie M. Weaver**, University of California, San Francisco, CA, USA

Molecular Mechanisms Promoting Tumor Metastasis to Lymph Nodes and Beyond\*

**Judith A. Varner**, University of California, San Diego Cancer Center, La Jolla, CA, USA

Cancer Therapeutic Agents Act Directly on Targets in the Microenvironment

**Michael B. Sporn**, Dartmouth Medical School, Hanover, NH, USA

Lymphatic Metastasis: How Tumor Cells Find the Best Escape Route

**Melody Swartz**, Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland

**2:30 PM-4:30 PM**      **Concurrent Session 4:  
Emerging Kinase Targets**  
Room 2020

**Chairperson: Judith S. Sebolt-Leopold**, JS Leopold Consulting, Ann Arbor, MI, USA

Genetic Predictors of MAP Kinase Dependence

**David B. Solit**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Targeting the IGF Receptor as Treatment for Cancer\*

**V. M. Macaulay**, Weatherall Institute of Molecular Medicine, Oxford, England

Exploiting the Kinome to Target Signaling and Cell Cycle Regulation\*

**Michelle D. Garrett**, Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, Sutton, England

Cell Growth Control by mTORC1 and S6K Signaling

**John Blenis**, Harvard Medical School, Boston, MA, USA

**4:30 PM-5:30 PM**      **Proffered Paper Session 2**  
Third Floor Ballroom

PR-5 Inhibition of CDK2 is a New Potential Therapy for Childhood Neuroblastoma Over-expressing N-Myc\*

**Jan J. Molenaar**, University of Amsterdam, Amsterdam, The Netherlands

PR-6 A Phase I Trial of the Heat Shock Protein 90 (HSP90) Inhibitor Alveospimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) Administered Weekly, Intravenously, to Patients with Advanced, Solid Tumors\*

**Simon C. Pacey**, The Institute of Cancer Research, Sutton, England

PR-7 Efficacy, Safety, and Changes in Angiogenic Markers Following Sunitinib Monotherapy in Patients with Advanced Hepatocellular Carcinoma: Experience from a Phase II Study\*

**Andrew X. Zhu**, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA

PR-8 Nerve-sparing Therapy with Oncolytic Herpes Virus for Cancers with Neural Invasion\*

**Ziv A. Gil**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.



**5:30 PM-7:30 PM**     **Poster Session B/Exhibits (continued)**  
First Floor Exhibit Hall

**10:30 AM-12:30 PM**     **Plenary Session 6: Towards Personalized Cancer Therapy**  
**Third Floor Ballroom**

## Thursday, October 25, 2007

**7:00 AM-8:00 AM**     **Continental Breakfast**  
Third Floor Lobby

**8:00 AM-10:00 AM**     **Plenary Session 5: Tumor Immunology**  
Third Floor Ballroom

**Chairperson: James P. Allison**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Immune Checkpoint Blockade in Cancer Therapy  
**James P. Allison**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Regulating Regulatory T Cells: A Novel Strategy to Augment Anti-tumor Immunity  
**Bernard A. Fox**, R. W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Portland, OR, USA

Failure at the Effector Phase: Immune Resistance in the Tumor Microenvironment\*  
**Thomas F. Gajewski**, University of Chicago, Chicago, IL, USA

Immunogenicity of Cytotoxic Drugs: Molecular Bases and Clinical Implementation\*  
**Laurence Zitvogel**, Institut Gustave-Roussy, Villejuif, France

**10:00 AM-10:30 AM**     **Coffee Break**  
Third Floor Lobby

**Chairperson: Tona M. Gilmer**, GlaxoSmithKline, Research Triangle Park, NC, USA

Molecular Diagnostics: A Need to Improve Cancer Care  
**Laura J. van't Veer**, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Integrated Genomic Test to Aid Treatment Selection  
**Lajos Pusztai**, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Optimizing Therapy through Pharmacogenomics  
**Kathleen D. Danenberg**, Response Genetics, Inc., Los Angeles, CA, USA

HER2/neu: A Practical Example  
**Clifford A. Hudis**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Panel Discussion

**12:30 PM-2:30 PM**     **Poster Session C/Exhibits**  
First Floor Exhibit Hall

**2:30 PM-4:30 PM**     **Concurrent Session 5: Cancer Cell Metabolism**  
Room 2001

**Chairperson: Craig B. Thompson**, University of Pennsylvania, Philadelphia, PA, USA

Therapeutic Targeting of Cancer Cell Metabolism  
**Craig B. Thompson**, University of Pennsylvania, Philadelphia, PA, USA

Cancer Cell Metabolism in the Crosshairs: Targeting the mTOR Pathway for Cancer Therapy\*  
**Robert T. Abraham**, Wyeth Pharmaceuticals, Pearl River, NY, USA

Role of the M2 Splice Isoform of Pyruvate Kinase in Tumor Cell Metabolism and Proliferation  
**Heather Christofk**, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Targeting Survivin in Cancer Therapy: Fulfilled Promises and Open Questions\*  
**Nadia Zaffaroni**, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.

**2:30 PM-4:30 PM**      **Concurrent Session 6:  
Rational Drug Combinations**  
Room 2007

**Chairperson: Roman Perez-Soler**, Montefiore Medical Center, Bronx, NY, USA

Synergistic Schedules with Combinations of EGFR Inhibitors and Cytotoxic Agents\*

**Roman Perez-Soler**, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

Epigenetic Therapies: What is the Target?

**Steven D. Gore**, Johns Hopkins University, Baltimore, MD, USA

Combinations with Angiogenesis Inhibitors

**John V. Heymach**, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

Multi-targeted Suppression of the RAS-AKT Signaling Network in NSCLC\*

**Hayley M. McDaid**, Albert Einstein College of Medicine, Bronx, NY, USA

**2:30 PM-4:30 PM**      **Concurrent Session 8:  
Re-Engineering Tumor  
Suppression**  
Room 2020

**Chairperson: Karen H. Vousden**, Beatson Institute for Cancer Research, Glasgow, Scotland

The p53 Tumor Suppressor as a Therapeutic Target

**Karen H. Vousden**, Beatson Institute for Cancer Research, Glasgow, Scotland

Overcoming the Loss of Mitochondrial Tumor Suppressors by Reactivating HIF Prolyl Hydroxylases\*

**Eyal Gottlieb**, Cancer Research UK Beatson Laboratories, Glasgow, Scotland

Targeting Bcl-2 Family Proteins to Treat Cancer\*

**Steven W. Elmore**, Abbott Laboratories, Abbott Park, IL, USA

Synthetic Lethal Approaches to the Treatment of Cancers with DNA Repair Defects\*

**Alan Ashworth**, Institute of Cancer Research, London, England

**2:30 PM-4:30 PM**      **Concurrent Session 7:  
Protein Stability and Turnover**  
Room 2014

**Chairperson: Neal Rosen**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Hsp90-dependent Protein Folding as a Therapeutic Target in Cancer

**Neal Rosen**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Discovery of MLN4924, a Novel, First in Class Nedd8 Activating Enzyme Inhibitor for the Treatment of Cancer\*

**Mark Rolfe**, Millennium Pharmaceuticals, Inc., Cambridge, MA, USA

Regulation of hsp90 Chaperone Activity by Acetylation\*

**Leonard M. Neckers**, National Cancer Institute, Bethesda, MD, USA

Exploiting Molecular Chaperone Addiction in Cancer: New Drugs and Biomarkers

**Paul Workman**, Cancer Research UK Centre for Cancer Therapeutics, Sutton, Surrey, England

**4:30 PM-5:30 PM**      **Proffered Paper Session 3**  
Third Floor Ballroom

PR-9 Study of Tumor Perfusion Parameters Obtained Using Dynamic Contrast Enhanced Ultrasonography (DCE-US) in a Phase I Trial of Patients Treated with Sorafenib and Dacarbazine\*

**Nathalie Lassau**, Institut Gustave Roussy, Villejuif, France

PR-10 MET Amplification Occurs with or without T790M Mutations in EGFR Mutant Lung Tumors with Acquired Resistance to Gefitinib or Erlotinib\*

**James Bean**, Memorial Sloan-Kettering Cancer Center, New York, NY, USA


PR-11 Inhibition of Colon Tumor Metastasis in Orthotopic Nude Mouse Models with the Dual-selective Src/Abl Kinase Inhibitor, AZD0530\*

**K. A. Phillips**, Departments of Surgical Oncology and Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

PR-12 AR47A6.4.2, a Functional Naked Monoclonal Antibody Targeting Trop-2, demonstrates *in vivo* Efficacy in Human Pancreatic, Colon, Breast and Prostate Cancer Models\*

**Amandine H. L. Truong**, Arius Research Inc., Toronto, ON, Canada

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.



**5:30 PM-7:30 PM**      **Poster Session C/Exhibits  
(continued)**  
First Floor Exhibit Hall

**10:30 AM-12:30 PM**      **Plenary Session 8:  
New Clinical Trial Design**  
Third Floor Ballroom

## Friday, October 26, 2007

**7:00 AM-8:00 AM**      **Continental Breakfast**  
Third Floor Lobby

**8:00 AM-10:00 AM**      **Plenary Session 7:  
Therapeutic Potential of  
Developmental Genes**  
Third Floor Ballroom

**Chairperson: Jon C. Aster**, Brigham and Women's Hospital, Boston, MA, USA

Targeting Notch in Cancer: Challenges and Opportunities  
**Jon C. Aster**, Brigham and Women's Hospital, Boston, MA, USA

Novel Molecular Targets in Breast Cancer Progression  
**Lewis A. Chodosh**, University of Pennsylvania, Philadelphia, PA, USA

Notch 1 Inhibitors in Mouse T-ALL Models  
**Michelle A. Kelliher**, University of Massachusetts Medical School, Worcester, MA, USA

Notch Antibody Antagonists for Cancer Therapy\*  
**Christian W. Siebel**, Genentech, Inc., South San Francisco, CA, USA

**10:00 AM-10:30 AM**      **Coffee Break**  
Third Floor Lobby

**Chairperson: James H. Doroshow**, National Cancer Institute, Bethesda, MD, USA

Potential Utilities of the Study of Circulating Tumor Cells in the Design of Clinical Trials of Molecularly Targeted Drugs\*

**Johann S. de Bono**, Royal Marsden Hospital, Sutton, England

New Concepts in Phase II Design

**Mark J. Ratain**, University of Chicago, Chicago, IL, USA

Clinical Trial Designs for Early Drug Development  
**James A. Zwiebel**, National Cancer Institute, Rockville, MD, USA

Title to Be Announced

**Francesco Pignatti**, The European Medicines Agency, London, England

Panel Discussion

**12:30 PM-12:45 PM**      **Closing Ceremony**  
Third Floor Ballroom

**Sara A. Courtneidge**, Scientific Committee Chairperson

\*An extended abstract for this presentation is available in the Invited Abstracts section of the *Proceedings*.